
RadSep’s Purification and Molecular Recognition Technology
February 19, 2026
RadSep, Inc., a subsidiary of IBC Advanced Technologies, Inc., provides state-of-the-art purification technology and novel chelators for medical radioisotopes and their precursors (Ac-225, Ra-224, Ra-225, Ra-226, Ra-228, Th-228, Th-232, Pb-212, Cu-67, and more).
RadSep offers Molecular Recognition Technology™ (MRT™) resins that are extremely selective, stable and simple to use. First-pass recoveries and purities of 99.9+% are achieved due to the high selectivity and capacity of MRT™ resins. In addition, their high radiolytic stability enables reuse for multiple separation cycles. MRT™ separation systems deliver maximum useable activity while minimizing manufacturing space and waste. Thus, MRT™ makes radioisotope production compatible with radiopharmaceutical manufacturing at scale.
As an award-winning manufacturer, RadSep also offers highly selective chelators for various radioisotopes.
Learn more at https://radsep.com
Recent News
- Canyon Labs Launches Expanded Reprocessing Validation Services for Medical Devices
- Connecting with Life Sciences in Logan
- Halia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Ratio Therapeutics Enters into Research Collaboration, License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
- Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
- Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India














